'WaldenBello's arrest is a violation of his fundamental rights, an affront to the institutions of Philippine democracy, and a threat to free expression everywhere.'
"There was no fiercer critic of the former dictator, Ferdinand Marcos, than Walden Bello," John Cavanagh, a senior adviser at the U.S.-based Institute for Policy Studies who has worked with Bello since meeting him in 1979, told"In pursuing a spurious libel suit against Walden, the dictator's son and his vice president, Sara Duterte, are opening a hornet's nest.
Weisbrot urged the U.S. State Department to speak out and noted that"Walden served on CEPR's board during most of its existence, and has been a longtime friend and ally." Asserting that the"fearless advocate for democracy, social justice, and human rights" was"unjustly arrested," the organization called the charges and arrest"clear acts of political persecution intended to intimidate, humiliate, and repress dissenters."
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer to buy South SF-based Global Blood Therapeutics in $5.4B dealPfizer will spend about $5.4 billion to buy Global Blood Therapeutics as the pharmaceutical giant continues to invest some of the cash influx reaped during the COVID-19 pandemic.
Read more »
Amid global growth, TaskUs cut 500 U.S. employees in second quarter as clients seek lower costsTaskUs has said it has more than 4,000 employees in the U.S., with most in New Braunfels, San Antonio and Harlingen.
Read more »
Pfizer agrees to buy Global Blood Therapeutics in deal valued at $5.4 billion: WSJPfizer Inc. undefined has reached an agreement to buy Global Blood Therapeutics Inc. [s :gbt] in a deal valued at $5.4 billion, the Wall Street Journal...
Read more »
Tiger Global joins $12 million funding round for gamer infrastructure startup LystoLysto has raised $12 million in pre-Series A funding. The firm provides tools for gamers to verify their credentials on a blockchain.
Read more »
Flush with cash, Pfizer buys Global Blood Therapeutics in $5.4 bln dealPfizer Inc on Monday agreed to pay $5.4 billion in cash for sickle cell disease drugmaker Global Blood Therapeutics , as it looks to capitalize on a surge in revenue from its COVID-19 vaccine and treatment.
Read more »
Pfizer Agrees to $5.4 Billion Deal for Global Blood TherapeuticsPfizer has agreed to buy Global Blood Therapeutics for $5.4 billion, a deal that will give the big drugmaker a foothold in the treatment of sickle-cell disease.
Read more »